Zobrazeno 1 - 10
of 191
pro vyhledávání: '"Etienne Giroux Leprieur"'
Autor:
Francesca Lucibello, MD, Valérie Gounant, MD, PhD, Mihaela Aldea, MD, PhD, Michaël Duruisseaux, MD, PhD, Maurice Perol, MD, Christos Chouaid, MD, Jaafar Bennouna, MD, PhD, Vincent Fallet, MD, Aldo Renault, MD, Florian Guisier, MD, PhD, Etienne Giroux-Leprieur, MD, PhD, Marie Wislez, MD, PhD, Anne-Claire Toffart, MD, PhD, Julien Mazieres, MD, PhD, Clémence Basse, MD, PhD, Nadia Hegarat, PhD, Matthieu Carton, MD, Nicolas Girard, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 6, Iss 1, Pp 100743- (2025)
Introduction: Pralsetinib is a RET inhibitor found to have antitumor activity in advanced, metastatic, RET fusion-positive NSCLC. Objective: To assess real-world efficacy of pralsetinib and treatment sequences in patients with RET fusion-positive NSC
Externí odkaz:
https://doaj.org/article/0c41f917b5ca448d96c9f58872859bd4
Autor:
Marie Bellouard, Jean Donadieu, Pauline Thiebot, Etienne Giroux Leprieur, Philippe Saiag, Isabelle Etting, Pamela Dugues, Emuri Abe, Jean-Claude Alvarez, Islam-Amine Larabi
Publikováno v:
Pharmaceutics, Vol 16, Iss 1, p 5 (2023)
Tyrosine kinase inhibitors (TKIs) are used as targeted cancer therapies in adults and have an off-label pediatric application for the treatment of Langerhans cell histiocytosis. A multitarget LC-MS/MS method was developed and validated for the determ
Externí odkaz:
https://doaj.org/article/4652bf71bb0b4d0eaf12ccc05c0b7f90
Publikováno v:
Thoracic Cancer, Vol 13, Iss 13, Pp 1994-1997 (2022)
Abstract Herein, we report a case of a 73‐year‐old female patient diagnosed with cT4N0M1a lung adenocarcinoma with KRAS G12C mutation, PDL1
Externí odkaz:
https://doaj.org/article/6866e454f7d94e888be29aa75ef9f6a4
Autor:
Geoffroy Bilger, Anne-Claire Toffart, Marie Darrason, Michaël Duruisseaux, Lucie Ulmer, Pascal Wang, Etienne Giroux Leprieur, Nicolas Girard, Marie Ange Massiani, Paul Bore, Renaud Descourt, Julian Pinsolle, Solene Valery, Isabelle Monnet, Aurélie Swalduz, Claire Tissot, Pierre Fournel, Anne Baranzelli, Alexis B. Cortot, Chantal Decroisette
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Introduction: Compared with docetaxel, the phase-III trial, ULTIMATE, showed a significant improvement of progression-free survival (PFS) with paclitaxel–bevacizumab combination (PB) as second- or third-line treatment in advanced non-small cell lu
Externí odkaz:
https://doaj.org/article/dacbea286c6e4222a88af607dd501e41
Autor:
Paul Takam Kamga, Aurélie Swalduz, Adrien Costantini, Catherine Julié, Jean-François Emile, Maurice Pérol, Virginie Avrillon, Sandra Ortiz-Cuaran, Pierre De Saintigny, Etienne Giroux-Leprieur
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Externí odkaz:
https://doaj.org/article/e09808814ffd413ba25263422512e420
Autor:
Paul Takam Kamga, Aurélie Swalduz, Adrien Costantini, Catherine Julié, Jean-François Emile, Maurice Pérol, Virginie Avrillon, Sandra Ortiz-Cuaran, Pierre de Saintigny, Etienne Giroux-Leprieur
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
IntroductionGrowing preclinical evidence has suggested that the Sonic hedgehog (Shh) pathway is involved in resistance to tyrosine kinase inhibitor (TKI) therapy for EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). However, little is known co
Externí odkaz:
https://doaj.org/article/24aef5e49a2543eea0b146bb648e47f9
Autor:
Julia Ouaknine Krief, Pierre Helly de Tauriers, Coraline Dumenil, Nathalie Neveux, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Julie Tisserand, Catherine Julie, Jean-François Emile, Thierry Chinet, Etienne Giroux Leprieur
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract Background Recent data suggested a role of gut microbiota and antibiotic use on immune checkpoint inhibitors efficacy. We aimed to evaluate the impact of early use of antibiotic (EUA), blood microbiome and plasmatic citrulline (marker of the
Externí odkaz:
https://doaj.org/article/1ac16da7d72d4360a71cc08abea4aa14
Autor:
Umberto Malapelle, Etienne Giroux Leprieur, Paul Takam Kamga, Marius Tresor Chiasseu, Christian Rolfo
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Externí odkaz:
https://doaj.org/article/29b93a7f3da94b5c988c43be935ae8e2
Autor:
Jean-François Emile, Coraline Dumenil, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Catherine Julie, Thierry Chinet, Etienne Giroux Leprieur, Zofia Hélias-Rodzewicz, Paul Takam Kamga, Adrien Costantini, Alexandre Corjon, Simon Garinet
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Despite prolonged tumor response to immune checkpoint inhibitors (ICIs) for a subset of patients with advanced non-small cell lung cancer (NSCLC), a secondary resistance will occur for a majority of these patients. The understanding of lat
Externí odkaz:
https://doaj.org/article/03dd415e5a6e46c3a728013a99b7763e
Autor:
Assya Akli, Nicolas Girard, Vincent Fallet, Gaelle Rousseau-Bussac, Valérie Gounant, Sylvie Friard, Jean Trédaniel, Cécile Dujon, Marie Wislez, Boris Duchemann, Etienne Giroux-Leprieur
Publikováno v:
Targeted Oncology. 17:675-682
Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in first line for the treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC).The identification of related histomolecular resistance mechani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::431d1ee56018a8f6ea2c37b57822655d
https://doi.org/10.1007/s11523-022-00915-9
https://doi.org/10.1007/s11523-022-00915-9